Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Lurbinectedin and Atezolizumab in Patients with Advanced Small Cell Lung Cancer Who Have Previously Received Platinum Chemotherapy

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on patients with Small Cell Lung Cancer that has advanced after previous treatment with platinum-based chemotherapy. The research evaluates a combination of two medications: lurbinectedin (also known as PM01183) and atezolizumab (Tecentriq). Both medications are given through intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of this research is to determine if this combination of medications is safe and effective for treating advanced Small Cell Lung Cancer. The study is divided into two parts. The first part aims to find the right dose of the medications that can be safely given together. The second part evaluates how well the treatment works in fighting the cancer.

During the study, participants receive regular infusions of both medications. Their cancer is monitored through regular imaging tests every six weeks to check how the treatment is working. The study team tracks any side effects and how well patients respond to the treatment. Some patients may also provide blood and tissue samples to help researchers better understand how the medications work in the body.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment preparation

    Before starting treatment, your doctor will perform tests to check your bone marrow, kidney, liver, and metabolic function. These tests must be completed within 7 days before starting the study.

    Your doctor will evaluate if you have measurable tumors that can be monitored during the treatment.

  2. Step 2

    Treatment administration

    You will receive two medications through an intravenous infusion: lurbinectedin (also known as PM01183) and atezolizumab (Tecentriq).

    The treatment will be given in cycles. Each infusion session will take place at the hospital.

  3. Step 3

    Regular monitoring

    Every 6 weeks (with a 2-week flexibility), you will have imaging tests to check how your tumors are responding to treatment.

    If the treatment appears to be working, additional scans will be performed at least 4 weeks later to confirm the positive response.

    Blood samples will be collected on the first day of each treatment cycle.

    Your doctor will monitor any side effects using standardized criteria to grade their severity.

  4. Step 4

    Ongoing assessments

    Treatment will continue until either your disease shows progression or you start a new cancer therapy.

    If your doctor notices potential benefits despite initial signs of tumor growth, they may continue the treatment and monitoring.

    Regular blood tests will continue throughout your treatment to ensure your safety.

  5. Step 5

    Post-treatment period

    After completing treatment, you must continue using effective contraception for at least 5 months following your last dose of atezolizumab.

    Women must continue contraception for 6 weeks and men for 4 months after the last dose of lurbinectedin.

Who can join the trial?

15 criteria

  • Must sign a voluntary informed consent document before starting any study procedures
  • Must be over 18 years old
  • Must have a confirmed diagnosis of small cell lung cancer through tissue or cell examination
  • Must have experienced disease progression after receiving platinum-based chemotherapy. There must be at least 30 days between the last chemotherapy dose and disease progression
  • Must have a performance status score of 0 or 1 (able to perform daily activities with minimal limitations)
  • Must have measurable disease that can be evaluated using specific criteria (called RECIST)
  • Must wait at least three weeks after any previous cancer treatment and recover from most side effects
  • Must have adequate:
    • Blood cell counts
    • Kidney function
    • Liver function
    • Metabolic function
    • For women who can become pregnant and men with partners who can become pregnant:
      • Must use effective birth control during the study
      • Women must continue birth control for 5 months after treatment
      • Men must continue birth control for 4 months after treatment
      • Men must not donate sperm during this period

Who cannot join the trial?

15 criteria

  • Prior treatment with atezolizumab (a type of immunotherapy medication)
  • History of autoimmune disease requiring systemic treatment in the past 2 years
  • Active or untreated brain metastases (cancer that has spread to the brain)
  • Significant heart problems in the past 6 months
  • Active or chronic liver disease
  • Known HIV infection or active hepatitis B or C
  • Other active cancers requiring treatment
  • Previous severe allergic reactions to similar medications
  • Pregnancy or breastfeeding
  • Inability to swallow oral medications
  • Major surgery within 4 weeks before starting the study
  • Any serious medical condition that could interfere with study participation
  • Current participation in other clinical trials
  • Use of live vaccines within 4 weeks before starting the study
  • Ongoing side effects from previous cancer treatments
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • PM01183 (Lurbinectedin)

    A medication used to treat small cell lung cancer. It works by blocking certain proteins that cancer cells need to grow and spread. It is typically used when cancer has progressed after initial chemotherapy treatment.

  • Atezolizumab

    An immunotherapy medication that helps the body's immune system fight cancer cells. It works by blocking a protein called PD-L1, which can help the immune system recognize and attack cancer cells. It is commonly used in the treatment of various types of cancer, including small cell lung cancer.

What is already known about the treatment

  • PM01183 (Lurbinectedin)

    A synthetic alkaloid administered intravenously that works by blocking transcription and inducing DNA double-strand breaks in cancer cells. Currently approved for treating metastatic small cell lung cancer in patients who have progressed after platinum-based chemotherapy. The medication functions by binding to DNA and disrupting the DNA repair process, leading to cancer cell death, and belongs to the class of transcription inhibitors.

  • Atezolizumab

    An immunotherapy medication administered through intravenous infusion that helps the immune system fight cancer cells. It works by blocking the PD-L1 protein on cancer cells, which allows T-cells to better recognize and attack cancer cells. This medication belongs to the class of checkpoint inhibitors and is currently approved for treating various types of cancers, including small cell lung cancer, with demonstrated effectiveness in clinical trials.

Investigated diseases

Small Cell Lung Cancer (SCLC) - A fast-growing type of lung cancer that develops from neuroendocrine cells in the lungs. It typically starts in the airways of the lungs and can spread quickly to other parts of the body. The disease is characterized by small, round cells that cluster together. SCLC can be classified into two stages: limited stage, where cancer is confined to one side of the chest, and extensive stage, where cancer has spread beyond one side of the chest. The condition can affect breathing and may cause symptoms such as persistent cough, chest pain, and shortness of breath. The disease commonly occurs in people with a history of smoking.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-517705-93-00Protocol code2SMALLEstimated enrolment140 patientsSponsorFundacion Oncosur

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).